Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in KRAS G12C mutant advanced solid tumors
NCT05002270Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), solid tumor (advanced stage), sponsored by Jacobio Pharmaceuticals. Started Sep 2021; status: completed.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05002270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002270.